Filtered By:
Drug: Medroxyprogesterone
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 487 results found since Jan 2013.
Efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate COX regression analysis
CONCLUSION: Age, pathological type, molecular typing, and myometrial infiltration were all relevant factors affecting the prognosis of early-stage high-risk endometrial cancer. The potential long-term prognostic benefit of adjuvant postoperative radiotherapy in patients with early-stage high-risk endometrial cancer is worthy of clinical consideration.PMID:37637703 | PMC:PMC10450383 | DOI:10.12998/wjcc.v11.i23.5447
Source: Cancer Control - August 28, 2023 Category: Cancer & Oncology Authors: Ding-Ran Wang Source Type: research
Effects of menopausal hormone therapy on erythrocyte n-3 and n-6 PUFA concentrations in the Women's Health Initiative randomized trial
CONCLUSIONS: HT increased RBC concentrations of the terminal n-3 and n-6 PUFAs (DHA and DPA n-6). These findings are consistent with an estrogen-induced increase in DHA and DPA n-6 synthesis, which is consistent with an upregulation of fatty acid elongases and/or desaturases in the PUFA synthetic pathway. The clinical implications of these changes require further study. The Women's Health Initiative Memory Study is registered at clinicaltrials.gov as NCT00685009. Note that the data presented here were not planned as part of the original trial, and therefore are to be considered exploratory.PMID:33710263 | DOI:10.1093/ajcn/nqaa443
Source: The American Journal of Clinical Nutrition - March 12, 2021 Category: Nutrition Authors: William S Harris Nathan L Tintle JoAnn E Manson Adam H Metherel Jennifer G Robinson Source Type: research
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
CONCLUSIONS: This surgical window trial rapidly accrued in a multisite setting and evaluated PR as its primary endpoint and Ki-67 as secondary endpoint. Despite no immediate effect of entinostat on PR in this short-term study, lessons learned can inform future window and treatment trials.PMID:33766814 | DOI:10.1158/1078-0432.CCR-20-4618
Source: Clinical Cancer Research - March 26, 2021 Category: Cancer & Oncology Authors: Linda R Duska Virginia L Filiaci Joan L Walker Laura L Holman Emily K Hill Richard G Moore Kari L Ring Michael L Pearl Carolyn Y Muller Christina L Kushnir Heather A Lankes Megan I Samuelson Kelley S Carrick Anand Rajan William H Rodgers Elise C Kohn Rich Source Type: research
Contraindications to Hormonal Contraception Among Postpartum Women in Texas
CONCLUSION: Nearly one in five participants had a category 3 or 4 contraindication to combined hormonal contraception. Patients at higher risk for adverse birth outcomes are more likely to have contraindications. Clinicians should counsel on contraception and contraindications prenatally to facilitate the most informed postpartum decision.PMID:33831931 | DOI:10.1097/AOG.0000000000004347
Source: Obstetrics and Gynecology - April 8, 2021 Category: OBGYN Authors: Kate Coleman-Minahan Elizabeth J Ela Kari White Daniel Grossman Source Type: research
